(IN BRIEF) Royal Philips and WellSpan Health have announced a seven-year strategic alliance to advance diagnostics, imaging, artificial intelligence, research and innovation across Central Pennsylvania and Northern Maryland. The collaboration will make Philips WellSpan’s preferred vendor for applicable imaging technologies, … Read the full press release
Posted in Artificial Intelligence (AI), Business, Electronics & Machinery, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Netherlands, Technology
Tagged 12 hospitals, ACO, AI-enabled care, ambulatory surgery centres, Amsterdam, artificial intelligence, care delivery, Central Pennsylvania, Central Pennsylvania healthcare, clinical training, co-development, community health system, cost efficiency, CT, diagnostic imaging, diagnostic imaging centres, diagnostics, digital health, digital X-ray, enterprise informatics, equipment planning, Healthcare Innovation, healthcare research, healthcare technology, image-guided therapy, imaging technology, joint innovation strategy, Medicare Accountable Care Organization, MR, MRI, Northern Maryland, Northern Maryland healthcare, operational performance, patient care quality, patient throughput, Philips, Philips and WellSpan Health Build Long-Term Platform for AI Diagnostics and Healthcare Technology Innovation, Philips and WellSpan Launch Research and Co-Development Alliance to Shape Future Care Delivery in Community Health, Philips Research, platform-based care, research agreement, Roxanna Gapstur, Roy Jakobs, Royal Philips, service planning, strategic alliance, technology lifecycle management, technology upgrades, ultrasound, value-based care, WellSpan Health, WellSpan Health and Philips Partner to Expand Advanced Imaging and AI Innovation Across Pennsylvania and Maryland, WellSpan Health Selects Philips as Preferred Imaging Technology Partner Under Landmark Innovation Agreement, WellSpan York Hospital, workflow efficiency, York Pennsylvania
(IN BRIEF) Wolters Kluwer has expanded its enterprise AI collaboration with OpenAI to support the development of trusted Expert AI solutions for regulated and high-stakes professional environments. The collaboration combines OpenAI’s latest enterprise AI capabilities with Wolters Kluwer’s curated content, … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Industrial, Investment, Law, Management, Netherlands, Technology
Tagged accountants, advisory insights, agentic AI, AI governance, Alex Tyrrell, Ashley Kramer, auditability, CCH Axcess Expert AI, Clinicians, compliance AI, corporate performance, data and document review, domain-grounded AI, enterprise AI, ESG, Euronext WKL, Expert AI, Fab, financial and corporate compliance, GenAI enablement platform, generative AI, Healthcare, healthcare AI, hospitals, lawyers, legal AI, legal and regulatory, OpenAI, professional decision-making, professional workflows, regulated professionals, regulatory workflows, Responsible AI Principles, tax and accounting AI, Tax and Legal Workflows, trusted AI, U.S. Enterprise Edition customers, UpToDate Expert AI, Wolters Kluwer, Wolters Kluwer Builds on OpenAI Collaboration to Scale Trusted Expert AI Across Critical Healthcare, Wolters Kluwer Expands Use of OpenAI Enterprise Capabilities to Support Governed AI Solutions for Regulated Professionals, workflow automation
(IN BRIEF) Fresenius Medical Care has launched kinexus worldwide as a unified digital platform designed to support home dialysis programs by combining remote therapy monitoring, prescription management, and supply-ordering workflows in one integrated system. The platform supports both peritoneal dialysis … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Bad Homburg, Care Enablement, connected care, dialysis treatment, digital health, European Renal Association Congress 2026, FME, FMS, Frankfurt Stock Exchange, Fresenius Medical Care, Fresenius Medical Care Advances Patient-Centered Home Dialysis Care with Global kinexus Platform Launch, Fresenius Medical Care Deutschland GmbH, Fresenius Medical Care Expands Connected Kidney Care with Global Launch of kinexus Home Dialysis Platform, Fresenius Medical Care Launches kinexus Worldwide to Strengthen Digital Support for Home Dialysis Programs, Glasgow, healthcare teams, home dialysis, home hemodialysis, home therapies, Huma Cloud Platform, Huma Therapeutics Limited, integrated supply ordering, Joe Turk, kidney care, kinexus, New York Stock Exchange, patient-centered care, peritoneal dialysis, remote prescription management, remote therapy monitoring, renal diseases, Scotland
(IN BRIEF) TeamViewer has strengthened its Assist AR remote assistance solution through a Microsoft collaboration that introduces AI-powered video enhancement using the Windows AI API for Video Super Resolution. The capability is designed to improve the clarity of incoming video … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Government, Healthcare, Industrial, Management, Media, Technology
Tagged AI video enhancement, Alfredo Patron, Assist AR, augmented reality, Copilot+ PCs, digital workplace, field engineers, field services, field technicians, Frankfurt Stock Exchange, frontline workers, Germany, Göppingen, Healthcare, industrial remote assistance, Intel, low-bandwidth environments, Manufacturing, Microsoft, Microsoft Build 2026, Mik Chernomordikov, on-device AI, remote guidance, remote support, San Francisco, SDAX, TeamViewer, TeamViewer Advances Industrial Remote Assistance with Microsoft On-Device AI for Clearer Real-Time Video, TeamViewer and Microsoft Strengthen Assist AR with AI-Powered Video Enhancement for Frontline Remote Support, TeamViewer Brings AI-Driven Video Clarity to Assist AR for Frontline Workers Across Industrial and Field Environments, TeamViewer Frontline, TeamViewer SE, utilities, Video Super Resolution, VSR, Windows 11, Windows AI API
(IN BRIEF) Foxconn, Radiall and Thales have inaugurated the next stage of Tessalia Technology SAS, a new joint venture in Le Barp, Nouvelle-Aquitaine, dedicated to Outsourced Semiconductor Assembly and Testing. Created within the framework of the EU Chips Act, Tessalia … Read the full press release
Posted in Automotive, Business, Electronics & Machinery, Environment, Financial, France, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Technology
Tagged advanced packaging, aerospace, Alain Rousset, automotive, Bob Wei-Ming Chen, Bordeaux, Choose France 2026 Summit, cleanrooms, electronics manufacturing, Emmanuel Macron, encapsulation technology, EU Chips Act, European semiconductor ecosystem, Foxconn, France, Hon Hai Technology Group, industrial competitiveness, Le Barp, made in Europe components, medical sectors, Nouvelle-Aquitaine, OSAT, Outsourced Semiconductor Assembly and Testing, Patrice Caine, PCBs, Pierre Gattaz, printed circuit boards, Radiall, Radiall and Thales Launch Tessalia to Strengthen European Semiconductor Packaging Capacity in France, reindustrialisation, Route des Lasers, Sébastien Martin, Semiconductor Packaging, SiP, strategic autonomy, supply chain resilience, System in Package, telecom infrastructure, Tessalia, Tessalia Foundation Stone Marks Major Step for European Semiconductor Value Chain Under EU Chips Act, Tessalia Technology SAS, Thales, ultra-high-density packaging, Young Liu
(IN BRIEF) Roche has received FDA acceptance under Priority Review for its New Drug Application for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative stage I-III breast cancer. The FDA is expected to decide on the application by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, American Society of Clinical Oncology Congress, ASCO 2026, Basel, breast cancer research, CDK4/6 inhibitor, early stage breast cancer, endocrine therapy, ER-positive breast cancer, ESR1-mutated breast cancer, evERA Breast Cancer, everolimus, FDA, FDA Accepts Roche’s Giredestrant Application as Potential New Adjuvant Treatment for Early-Stage Breast Cancer, FDA Sets November 2026 Decision Date for Roche’s Giredestrant in Early-Stage ER-Positive Breast Cancer, giredestrant, HER2-negative breast cancer, hyaluronidase, iDFS, invasive disease-free survival, Levi Garraway, lidERA Breast Cancer, NDA, New Drug Application, oncology, overall survival, Palbociclib, PDUFA, pertuzumab, Phesgo, Prescription Drug User Fee Act, Priority Review, Roche, Roche Moves Forward With Giredestrant Filing in Curative-Intent Breast Cancer Treatment Setting, Roche Secures FDA Priority Review for Giredestrant in Early-Stage ER-Positive Breast Cancer, selective oestrogen receptor degrader, SERD, stage I breast cancer, stage II breast cancer, stage III breast cancer, targeted therapy, trastuzumab, United States Food and Drug Administration
(IN BRIEF) Scania has launched its first battery-electric CrewCab, the CP31L 4×2, designed for fire, airport and civil rescue operations. The new vehicle supports zero tailpipe emission transport while offering the operational strength required for emergency and mission-critical environments. With … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, Sweden, Technology, Transportation & Logistics
Tagged 356 kWh battery capacity, 90 percent state-of-charge window, Airport and Civil Rescue Operations, Airport and Recovery, airport rescue vehicles, battery-electric CrewCab, battery-electric truck, BEV CrewCab, bodybuilder flexibility, civil rescue operations, crew comfort, electric trucks, emergency services, emergency vehicles, Fire & Rescue, fire rescue vehicles, Fleet Electrification, free frame sides, Louise Johansson, low-emission transport, operational reliability, rescue operations, Scania, Scania Advances Fleet Electrification for Emergency Services with New Battery-Electric CrewCab, Scania Commercial, Scania CP31L 4x2, Scania Launches First Battery-Electric CrewCab for Fire, Scania Strengthens Fire and Rescue Vehicle Offering with Purpose-Built Electric CrewCab, sustainable transport, uptime, zero tailpipe emissions, Zero-Emission Transport
(IN BRIEF) The University of Warwick-coordinated OPTIMA trial, sponsored by University College London, has found that the Prosigna genomic test could help many patients with early-stage hormone-sensitive breast cancer avoid unnecessary chemotherapy without compromising outcomes. The trial followed more than … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Adrienne Morgan, American Society of Clinical Oncology, ASCO Annual Meeting, breast cancer, breast oncology, cancer recurrence, cancer research, Cardiff, chemotherapy, clinical trial, early stage breast cancer, gene test, genomic test, hormone therapy, hormone-sensitive breast cancer, Independent Cancer Patients’ Voice, Karen Bonham, lymph nodes, Major OPTIMA Trial Results Could Support Wider NHS Use of Genomic Testing to Reduce Chemotherapy Overtreatment, National Institute for Health and Care Research, NHS, NHS laboratories, Nice, NIHR, OPTIMA trial, Patient and Public Involvement, patient outcomes, personalised treatment, Professor Janet Dunn, Professor Rob Stein, Prosigna, radiotherapy, treatment decision-making, tumour biology, UCL, UCL Cancer Institute, University College London, University of Warwick, University of Warwick and UCL-Led Breast Cancer Trial Highlights Potential to Spare Thousands from Chemotherapy, University of Warwick-Coordinated OPTIMA Trial Shows Genomic Test Could Help Breast Cancer Patients Avoid Unnecessary Chemotherapy, unnecessary chemotherapy, Veracyte Inc, Warwick Clinical Trials Unit
(IN BRIEF) Novartis will present 31 abstracts across its immunology portfolio at EULAR 2026 in London, highlighting new data for Cosentyx, ianalumab and rap-cel in several high-burden autoimmune diseases. Key presentations include results from REPLENISH, the largest global Phase III … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged Angelika Jahreis, AUTOGRAPH-IIM, AUTOGRAPH-SSC, autoimmune diseases, Basel, biologics, CAR-T cell therapy, CD19-directed therapy, clinical data, Cosentyx, EULAR 2026, European Alliance of Associations for Rheumatology, FUTURE 1, FUTURE 5, ianalumab, Ianalumab and Rap-Cel Data Across Rheumatology and Autoimmune Disease Research, idiopathic inflammatory myopathies, immunology, June 2026, London, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Advances Immunology Pipeline with 31 Abstracts Accepted for EULAR 2026 Congress in London, Novartis Highlights New Cosentyx, Novartis to Share Phase III and CAR-T Therapy Data Supporting Momentum in Complex Autoimmune Diseases, Phase II Study, Phase III Trial, polymyalgia rheumatica, psoriatic arthritis, rap-cel, rapcabtagene autoleucel, REPLENISH trial, rheumatology, secukinumab, Sjögren’s disease, systemic lupus erythematosus, systemic sclerosis, VAY736, YTB323
(IN BRIEF) The Institute of Cancer Research, London, has presented encouraging results from the phase Ib/II OrigAMI-4 clinical trial, showing that the targeted immunotherapy drug amivantamab shrank tumours in 42 per cent of patients with recurrent and/or metastatic head and … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, amivantamab, Amivantamab Demonstrates Encouraging Survival and Tumour Shrinkage Outcomes in Hard-to-Treat Head and Neck Cancer Patients, ASCO Annual Meeting, bispecific monoclonal antibody, cancer research, Carl Walsh, clinical trial, complete response, EGFR, head and neck squamous cell carcinoma, HNSCC, ICR, immunotherapy, Johnson & Johnson, Met, metastatic head and neck cancer, oncology, OrigAMI-4, OrigAMI-5, outpatient cancer treatment, partial response, phase Ib II trial, Phase III Trial, platinum-based chemotherapy, Professor Kevin Harrington, Professor Kristian Helin, recurrent head and neck cancer, Subcutaneous Injection, targeted cancer treatment, Targeted Immunotherapy Injection Shows Strong Clinical Activity in Patients with Treatment-Resistant Head and Neck Cancer, The Institute of Cancer Research and Royal Marsden Team Advance Clinical Evidence for Injectable Head and Neck Cancer Treatment, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, treatment-resistant cancer, tumour shrinkage
(IN BRIEF) Symrise AG has launched SYM ALPHA™ Think Tank, a new co-creation and insight platform for selected partners in its Scent & Care segment. The platform focuses on Generation Alpha, estimated at around 2.5 billion people globally in 2026, … Read the full press release
Posted in Apparel, Fashion & Beauty, Artificial Intelligence (AI), Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, Science, Technology
Tagged AI validation, behavioral insights, brand experiences, Cheryl Morano, co-creation platform, consumer culture, consumer fragrance, consumer insights, cultural intelligence, early-stage validation, formats, fragrance innovation, future-ready innovation, Gen Alpha, Generation Alpha, generational intelligence, go-to-market decisions, identity, innovation strategy, market relevance, Paula Limena, Product Development, R&D focus, Rituals, Scent & Care, sensory co-creation, strategic partners, SYM ALPHA, SYM ALPHA Think Tank, Symrise, Symrise AG, Symrise Introduces New Co-Creation Platform to Turn Generation Alpha Insights Into Faster Innovation Decisions, Symrise Launches SYM ALPHA™ Think Tank to Help Brands Build Products for Generation Alpha, Symrise Scales Generation Alpha Insight Platform to Strengthen Product Development Across Scent & Care, Symrise Uses Cultural Intelligence and Sensory Co-Creation to Help Brands Prepare for Future Consumers, textures
(IN BRIEF) Unilever plans to invest $270 million in a new Global Innovation Centre in New Haven, Connecticut, scheduled to open by spring 2029. The facility will become a major R&D hub for the company’s personal care, beauty and wellbeing … Read the full press release
Posted in Apparel, Fashion & Beauty, Artificial Intelligence (AI), Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI-powered innovation, artificial intelligence, Beauty and Wellbeing Product Development, beauty innovation, Biosciences, Cleansing, Connecticut, consumer goods innovation, consumer insights, fragrance development, Global Innovation Centre, Herrish Patel, human performance lab, microbiome, Ned Lamont, neuroscience, New Haven, packaging innovation, personal care, Personal Care and Wellbeing in New Haven, Personal Care North America, polycultural skin and hair centre of excellence, Product Development, quantum capabilities, R&D, research and development, Richard Slater, science-led innovation, skin biology, skin care, skin-brain axis, Trumbull Connecticut, U.S. investment, Unilever, Unilever Chief Research and Development Officer, Unilever Expands U.S. R&D Footprint with AI-Powered Global Innovation Centre in Connecticut, Unilever Fragrance House, Unilever Plans New Connecticut Innovation Hub to Accelerate Personal Care, Unilever Strengthens Global R&D Strategy with $270 Million Investment in New Haven Innovation Centre, Unilever to Invest $270 Million in New Global Innovation Centre for Beauty, Unilever USA, wellbeing
(IN BRIEF) Royal Philips and The Walt Disney Company are introducing Disney stories and characters into Philips Ambient Experience for MRI, bringing a more child-friendly and emotionally supportive imaging environment to medical facilities in 87 countries. The collaboration is designed … Read the full press release
Posted in Business, Electronics & Machinery, Entertainment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Netherlands, Science, Technology
Tagged Ambient Experience for MRI, Atul Gupta, Calderdale Royal Hospital, child-friendly healthcare, children’s hospitals, diagnostic imaging, Disney, Disney Princesses, Disney Stories Join Philips Ambient Experience for MRI to Support Calmer Pediatric Imaging Exams Worldwide, Emilio J Inarejos Clemente, Healthcare Innovation, hospital comfort, immersive healthcare technology, Lisa Haines, Marvel, medical imaging, Mickey Mouse, Minnie Mouse, MRI anxiety, MRI exams, patient experience, patient-centered care, pediatric healthcare, pediatric MRI, pediatric radiology, Philips Ambient Experience, Philips and Disney Introduce Character-Led MRI Experience to Help Reduce Anxiety for Children in Hospitals, Philips and The Walt Disney Company Bring Immersive Disney-Themed Content to MRI Rooms in 87 Countries, Rady Children’s Health, Royal Philips, Sant Joan de Déu Hospital, Star Wars, The Walt Disney Company
(IN BRIEF) Solvay and Pantys have agreed to a new three-year partnership that will expand their work in menstrual health, inclusion and verified social impact. Building on a collaboration that began in 2017, the partnership connects Solvay’s sustainable chemistry and … Read the full press release
Posted in Apparel, Fashion & Beauty, Belgium, Business, Chemicals, Environment, Healthcare, News, Society
Tagged Amni® Soul Eco, Coatis Business Unit, community programs, Corporate Social Responsibility, education programs, Emily Ewell, FemTech, health and well-being, high-performance textiles, Inclusion, Inclusion and Community Well-Being, inclusive innovation, incontinence care, menstrual health, Pantys, Pantys and Solvay to Scale Social Credits Model for Health, Philippe Kehren, product donations, reusable underwear, S&P Global registry, social credits, social impact measurement, Solvay, Solvay and Pantys Advance Three-Year Partnership Combining Sustainable Textiles with Measurable Social Outcomes, Solvay and Pantys Build New Social Impact Framework for Menstrual Health and Inclusion Programs, sustainable chemistry, sustainable textiles, traceability, United Nations Sustainable Development Goals, verified social impact, Vulnerable Communities, W+ Standard, WOCAN, Women’s Health
(IN BRIEF) ZEISS Ventures has participated in the latest funding round of Maculaser, a Finnish medtech company developing a patented, non-damaging, temperature-controlled retinal laser therapy. The round, co-led by ZEISS Ventures and M2care, will help Maculaser begin clinical development of … Read the full press release
Posted in Business, Financial, Finland, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Science, Technology
Tagged Aalto University, age-related macular degeneration, AMD, cellular defence mechanisms, clinical development, data-driven laser therapy, diabetic maculopathy, Early Intervention, Finland, Finnish medtech, Germany, healthtech, Jani Tirronen, late-stage AMD, M2care, Maculaser, Maculaser Advances Temperature-Controlled Retinal Laser Technology With Support From ZEISS Ventures and M2care, medical technology, non-damaging treatment, OBERKOCHEN, ophthalmic innovation, ophthalmologists, outpatient procedure, personalised retinal treatment, proactive vision preservation, Prof Dr Boris Hofmann, real-time temperature control, repeatable treatment, retinal diseases, retinal laser therapy, retinal tissue, severe vision loss, temperature-controlled laser therapy, vision loss prevention, ZEISS, ZEISS Backs Finnish Medtech Maculaser in Development of Data-Driven Laser Therapy for Retinal Diseases, ZEISS Group, ZEISS Ventures, ZEISS Ventures Investment Supports Maculaser’s Effort to Shift Retinal Care Toward Earlier Vision Preservation, ZEISS Ventures Invests in Maculaser to Advance Non-Damaging Retinal Laser Therapy for Earlier Eye Disease Treatment, ZEISS Ventures Invests in Maculaser to Support Development of Temperature-Controlled Retinal Laser Therapy
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 13.3 million from BARDA to continue development of ceftibuten-ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase inhibitor antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The latest tranche brings BARDA’s total … Read the full press release
Posted in Business, Economy, Financial, Government, Healthcare, Industrial, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged Administration for Strategic Preparedness and Response, Allschwil, antibiotic resistance, antimicrobial resistance, ASPR, BARDA, BARDA Funding Supports Basilea’s Efforts to Address Unmet Need in Oral Treatment of Complicated Urinary Tract Infections, Basilea, Basilea Pharmaceutica Ltd, Basilea Receives Additional USD 13.3 Million BARDA Funding to Advance Novel Oral Antibiotic Development, Basilea Secures Additional Non-Dilutive Funding to Prepare Ceftibuten-Ledaborbactam for Phase 3 Development, Basilea Secures Additional USD 13.3 Million BARDA Funding to Advance Development of Novel Oral Antibiotic Ceftibuten-Ledaborbactam, beta-lactam, beta-lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI combination, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, Gram-negative bacteria, infectious diseases, KPC, ledaborbactam etzadroxil, MDR Enterobacterales, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, OXA-48, phase 3 programme, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, SIX: BSLN, Switzerland, U.S Department of Health and Human Services, U.S. FDA
(IN BRIEF) Sanofi has received FDA priority review for the new drug application for venglustat, an investigational oral glucosylceramide synthase inhibitor being developed for type 3 Gaucher disease. The FDA’s target action date is 25 November 2026. If approved, venglustat … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged adult patients, ataxia, biopharma, blood-brain barrier, breakthrough therapy designation, central nervous system, cerebrospinal fluid, cognitive deficits, enzyme replacement therapy, ERT, EURONEXT: SAN, Fabry disease, Fast Track Designation, FDA, Gaucher disease, GCSi, GD3, GL1, glucosylceramide synthase inhibitor, glycosphingolipids, GSL, haemoglobin, LEAP2MONO, liver volume, lyso-GL1, lysosomal storage disease treatments, lysosomal storage disorder, Nasdaq SNY, NCT05222906, NDA, neuroinflammation, neurological manifestations, New Drug Application, orphan designation, paediatric patients, Paris, phase 3 study, platelet count, Priority Review, rare diseases, Sanofi, Sanofi Builds Rare Disease Pipeline as FDA Accepts Venglustat Application for Priority Review in GD3, Sanofi’s Venglustat Could Become First U.S. Treatment Targeting Neurological Symptoms of Type 3 Gaucher Disease, Sanofi’s Venglustat Receives FDA Priority Review for Potential Treatment of Type 3 Gaucher Disease, Sanofi’s Venglustat Receives FDA Priority Review for Type 3 Gaucher Disease Treatment in the United States, spleen volume, type 3 Gaucher disease, U.S. Food and Drug Administration, venglustat, WORLDSymposium
(IN BRIEF) Novartis will present data from 15 abstracts across its kidney disease portfolio at the European Renal Association Congress 2026 in Glasgow from June 3 to 6. The presentations include late-breaking Phase III data for Vanrafia® from the ALIGN … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged 124-week data, ADPKD, ALIGN trial, anti-APRIL therapy, anti-miR-17 oligonucleotide, APPLAUSE-IgAN, APPRISE-C3G, atrasentan, autosomal dominant polycystic kidney disease, Basel, C3 glomerulopathy, C3G, C3G and ADPKD Data at European Renal Association Congress, cardiovascular renal and metabolic development, dialysis, EGFR, ERA 2026, European Renal Association Congress, Fabhalta, farabursen, Glasgow, IgA nephropathy, IgAN, IgNITE, immune-mediated kidney diseases, iptacopan, June 2026, kidney care, kidney disease, kidney function, late-breaking data, Novartis, Novartis Advances Kidney Disease Research with New IgAN, Novartis Highlights Expanding Renal Pipeline and Disease Insights at ERA 2026 in Glasgow, Novartis Presents New Evidence Supporting Future Treatment Approaches in IgA Nephropathy and C3 Glomerulopathy, Novartis Strengthens Kidney Care Portfolio with New Scientific Data Across Progressive Immune-Mediated Renal Diseases, Novartis to Showcase Phase III Vanrafia and Fabhalta Data Alongside Long-Term Zigakibart Results at ERA 2026, phase I/II data, Phase III data, real-world evidence, renal disease, renal portfolio, Ruchira Glaser, transplantation, Vanrafia, zigakibart
(IN BRIEF) Fresenius Medical Care has announced a new share buyback program with a total volume of around EUR 1 billion, to be executed in tranches over 12 months from the start of the program. The buyback is expected to … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology
Tagged Annual General Meeting, April 30 2026, Bad Homburg, capital allocation, dialysis clinics, dialysis machines, dialysis treatment, dialyzers, Dividend Payments, EUR 1 billion, financial discipline, FME, FME Reignite strategy, FMS, Frankfurt Stock Exchange, Fresenius Medical Care, Fresenius Medical Care AG, Fresenius Medical Care Announces New EUR 1 Billion Share Buyback Program Following Completion of Previous Program, Fresenius Medical Care Announces New EUR 1 Billion Share Buyback Program to Support Shareholder Value Creation, Fresenius Medical Care Launches New Capital Return Initiative with Planned EUR 1 Billion Share Buyback, Fresenius Medical Care Reinforces Capital Allocation Discipline with New EUR 1 Billion Share Repurchase Program, Fresenius Medical Care to Execute New Share Buyback Program in Tranches Over 12 Months, Healthcare, Helen Giza, kidney care, Martin Fischer, May 21 2026, medical products, medical services, New York Stock Exchange, operating cash flow, renal care, renal diseases, Share Buyback Program, share repurchase, shareholder returns, treasury shares, value creation
(IN BRIEF) A new study led through collaboration between The Institute of Cancer Research, the Karolinska Institute, and Uppsala University has found that some cases of iAMP21, a rare high-risk subtype of paediatric acute lymphoblastic leukaemia, may begin before birth. … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged all®, bone marrow, cancer evolution, Center for Medical Mass Screening in Sweden, childhood cancer research, childhood leukaemia, chromosome 21 amplification, clonal evolution, Dr Gustaf Leijonhufvud, Dr Tony Ford, Dr Viktor Ljungström, Early Detection, genetic alterations, genetic rearrangement, Haematologica, heel prick tests, high-risk leukaemia, iAMP21, ICR, intrachromosomal amplification of chromosome 21, Karolinska Institute, Karolinska University Hospital, London, lymphocytes, May 26 2026, neonatal blood spots, New ICR-Led Research Traces Early Genetic Origins of High-Risk Childhood Leukaemia to Neonatal Blood Samples, New Study Shows Neonatal Blood Spots Can Reveal Early Genetic Alterations Associated with iAMP21 Leukaemia, paediatric acute lymphoblastic leukaemia, paediatric cancer, pre-ALL clone, pre-leukaemic changes, prenatal origins, Professor Britt Gustafsson, Professor Sir Mel Greaves, Researchers Uncover Evidence That Rare Childhood Leukaemia Subtype Can Begin Years Before Diagnosis, Sweden, Swedish Childhood Cancer Society, The Institute of Cancer Research, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype Can Begin Before Birth, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype May Originate Before Birth, United Kingdom, Uppsala University
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?